# SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Source: https://onco.cc/trials/nct06743126/  
OnCo record `nct06743126` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing IMA203 in melanoma, now recruiting.

## Summary

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma is a phase 3 interventional study registered as NCT06743126, led by Immatics US, and recruiting on the registry. Official title: A Prospective, Multicenter, Open-label, Randomised, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301). Planned enrolment is 360 participants (estimated). The study started in 2025-01-14 and primary completion is expected in 2028-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: SUPRAME
- Tags: ctgov-ingest
- Registry id: NCT06743126
- Phase: 3
- Setting: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)
- Sponsor: Immatics US
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT06743126: https://clinicaltrials.gov/study/NCT06743126

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IMA203](https://onco.cc/drugs/ima203/)
- companies: [Immatics](https://onco.cc/companies/immatics/)

---
JSON: https://onco.cc/api/v1/entities/nct06743126.json